| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chia-Hung Lin, Sheng-Hwu Hsieh, Jui-Hung Sun, Jir-Shiong Tsai, Yu-Yao Huan. Glucose Variability and β- Cell Response by GLP-1 Analogue added-on CSII for Patients with Poorly Controlled Type 2 Diabetes. Scientific reports. vol 5. 2016-09-26. PMID:26607841. |
the effects of twice-daily glp-1 analogue injections added on continuous subcutaneous insulin infusion (csii) in patients with poorly controlled type 2 diabetes (t2dm) were unknown. |
2016-09-26 |
2023-08-13 |
Not clear |
| Hidetaka Hamasaki, Sumie Moriyama, Hidekatsu Yana. A possible difference in the mechanism for postprandial hypoglycemia associated with dumping syndrome between patients with and without type 2 diabetes. Obesity research & clinical practice. vol 9. issue 6. 2016-09-22. PMID:26321136. |
we investigated the changes in plasma glucose, serum insulin, plasma glucagon, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1) by the 75 g oral glucose tolerance test (ogtt) in 3 patients with and without type 2 diabetes who had gastric surgery. |
2016-09-22 |
2023-08-13 |
Not clear |
| Baptist Gallwit. Novel Therapeutic Approaches in Diabetes. Endocrine development. vol 31. 2016-09-19. PMID:26824365. |
incretin-based therapies utilize the effects of glucagon-like peptide-1 (glp-1), which stimulates insulin and inhibits glucagon secretion in a glucose-dependent manner. |
2016-09-19 |
2023-08-13 |
Not clear |
| Valeria Calsolaro, Paul Ediso. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases. CNS drugs. vol 29. issue 12. 2016-09-15. PMID:26666230. |
novel glp-1 (glucagon-like peptide-1) analogues and insulin in the treatment for alzheimer's disease and other neurodegenerative diseases. |
2016-09-15 |
2023-08-13 |
Not clear |
| Valeria Calsolaro, Paul Ediso. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases. CNS drugs. vol 29. issue 12. 2016-09-15. PMID:26666230. |
several studies have shown the importance of both insulin and glp-1 signalling on cognitive function, and many preclinical studies have been performed to evaluate the potential protective role of glp-1 on the brain. |
2016-09-15 |
2023-08-13 |
Not clear |
| Valeria Calsolaro, Paul Ediso. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases. CNS drugs. vol 29. issue 12. 2016-09-15. PMID:26666230. |
here we review the underlying mechanism of insulin and glp-1 signalling in the cns, as well as the preclinical data for the use of glp-1 analogues such as liraglutide, exenatide and lixisenatide in neurodegenerative diseases. |
2016-09-15 |
2023-08-13 |
Not clear |
| Mabrouk El-Sabagh, Dai Taniguchi, Toshihisa Sugino, Taketo Obitsu, Kohzo Taniguch. Insulin-independent actions of glucagon-like peptide-1 in wethers. Animal science journal = Nihon chikusan Gakkaiho. vol 86. issue 4. 2016-09-12. PMID:25439266. |
four suffolk mature wethers (60.0 ± 6.7 kg body weight (bw)) were intravenously infused with insulin (0.5 mu/kg bw/min; from 0 to 90 min) and glp-1 (0.5 μg/kg bw/min; from 60 to 150 min) with both hormones co-administered from 60 to 90 min, in a repeated-measure design under euglycemic clamp for 150 min, to investigate whether glp-1 has insulin-independent actions. |
2016-09-12 |
2023-08-13 |
Not clear |
| Mabrouk El-Sabagh, Dai Taniguchi, Toshihisa Sugino, Taketo Obitsu, Kohzo Taniguch. Insulin-independent actions of glucagon-like peptide-1 in wethers. Animal science journal = Nihon chikusan Gakkaiho. vol 86. issue 4. 2016-09-12. PMID:25439266. |
insulin plus glp-1 infusion induced a greater increase (p < 0.05) in plasma concentrations of insulin and triglyceride (tg), but decreased (p < 0.05) glucagon, total cholesterol (t-cho), neaa and un plasma concentrations. |
2016-09-12 |
2023-08-13 |
Not clear |
| Mabrouk El-Sabagh, Dai Taniguchi, Toshihisa Sugino, Taketo Obitsu, Kohzo Taniguch. Insulin-independent actions of glucagon-like peptide-1 in wethers. Animal science journal = Nihon chikusan Gakkaiho. vol 86. issue 4. 2016-09-12. PMID:25439266. |
in conclusion, glp-1 exerts extrapancreatic roles in ruminants not only insulin-independent but probably, in contrast to non-ruminants, antagonistic to insulin effects. |
2016-09-12 |
2023-08-13 |
Not clear |
| Akira Hirasaw. [Free Fatty Acid Receptor Family: A New Therapeutic Target for Metabolic Diseases]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. vol 135. issue 6. 2016-09-12. PMID:26028412. |
ffar1 regulates insulin secretion in pancreatic β-cells, whereas ffar4 promotes the secretion of glucagon-like peptide-1 (glp-1) in the intestine, and also acts as a lipid sensor in adipose tissue to sense dietary fat and control energy balance. |
2016-09-12 |
2023-08-13 |
Not clear |
| Darleen Sandoval, Stephanie R Sisle. Brain GLP-1 and insulin sensitivity. Molecular and cellular endocrinology. vol 418 Pt 1. 2016-09-09. PMID:25724479. |
brain glp-1 and insulin sensitivity. |
2016-09-09 |
2023-08-13 |
Not clear |
| Darleen Sandoval, Stephanie R Sisle. Brain GLP-1 and insulin sensitivity. Molecular and cellular endocrinology. vol 418 Pt 1. 2016-09-09. PMID:25724479. |
glp-1 analogs were long presumed to affect glucose control through their ability to increase insulin levels through peripheral action on beta cells. |
2016-09-09 |
2023-08-13 |
Not clear |
| Darleen Sandoval, Stephanie R Sisle. Brain GLP-1 and insulin sensitivity. Molecular and cellular endocrinology. vol 418 Pt 1. 2016-09-09. PMID:25724479. |
in this review we will discuss the evidence for a central glp-1 system and the effects of glp-1 in the brain on regulating multiple facets of glucose homeostasis including glucose tolerance, insulin production, insulin sensitivity, hepatic glucose production, muscle glucose uptake, and connections of the central glp-1 system to the gut. |
2016-09-09 |
2023-08-13 |
Not clear |
| Paul L McCormac. Evogliptin: First Global Approval. Drugs. vol 75. issue 17. 2016-09-09. PMID:26541763. |
dpp-4 inhibitors control glucose levels by preventing the breakdown of the incretin hormones glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), which stimulate insulin secretion in response to the increased levels of glucose in the period following meals. |
2016-09-09 |
2023-08-13 |
Not clear |
| Csaba Hegedűs, Diána Kovács, Rita Kiss, Réka Sári, József Németh, Zoltán Szilvássy, Barna Peit. Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats. Journal of psychopharmacology (Oxford, England). vol 29. issue 12. 2016-09-07. PMID:26349558. |
fasted and post-prandial blood samples were obtained for plasma insulin, leptin, ghrelin, amylin, glp-1, gip, pyy and pp determination. |
2016-09-07 |
2023-08-13 |
rat |
| Ai-Jun Li, Qing Wang, Thu T Dinh, Steve M Simasko, Sue Ritte. Mercaptoacetate blocks fatty acid-induced GLP-1 secretion in male rats by directly antagonizing GPR40 fatty acid receptors. American journal of physiology. Regulatory, integrative and comparative physiology. vol 310. issue 8. 2016-08-30. PMID:26791830. |
gpr40 mediates fa-induced secretion of the satietogenic incretin peptide glucagon-like peptide 1 (glp-1), by enteroendocrine l cells, as well as fa-induced enhancement of glucose-stimulated insulin secretion. |
2016-08-30 |
2023-08-13 |
rat |
| Ai-Jun Li, Qing Wang, Thu T Dinh, Steve M Simasko, Sue Ritte. Mercaptoacetate blocks fatty acid-induced GLP-1 secretion in male rats by directly antagonizing GPR40 fatty acid receptors. American journal of physiology. Regulatory, integrative and comparative physiology. vol 310. issue 8. 2016-08-30. PMID:26791830. |
in vivo, ma reduced glp-1 secretion following olive oil gavage while also increasing glucose and decreasing insulin levels. |
2016-08-30 |
2023-08-13 |
rat |
| Sarah L Anderson, Jennifer M Trujill. Basal Insulin Use With GLP-1 Receptor Agonists. Diabetes spectrum : a publication of the American Diabetes Association. vol 29. issue 3. 2016-08-30. PMID:27574369. |
basal insulin use with glp-1 receptor agonists. |
2016-08-30 |
2023-08-13 |
Not clear |
| Mehul R Dalal, Lin Xie, Onur Baser, Andres DiGeni. Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 21. issue 1. 2016-08-29. PMID:25148821. |
adding rapid-acting insulin or glp-1 receptor agonist to basal insulin: outcomes in a community setting. |
2016-08-29 |
2023-08-13 |
Not clear |
| Mehul R Dalal, Lin Xie, Onur Baser, Andres DiGeni. Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. vol 21. issue 1. 2016-08-29. PMID:25148821. |
to evaluate real-world outcomes in patients with type 2 diabetes mellitus (t2dm) receiving basal insulin who initiate add-on therapy with a rapid-acting insulin (rai) or a glucagon-like peptide 1 (glp-1) receptor agonist. |
2016-08-29 |
2023-08-13 |
Not clear |